Large-scale clinical validation studies are needed to assess the expression levels of GRB7 in ovarian cancer patient samples and the association of GRB7 expression with clinicopathological parameters such as tumor stage, grade, even if our systematic analysis of multiomics data has helped us understand the expression pattern of GRB7. This evidence concerns the gene GRB7 and neoplasm.